142 related articles for article (PubMed ID: 35790787)
1. Development and validation of a multivariable prognostic model in de novo metastatic castrate sensitive prostate cancer.
Roy S; Sun Y; Wallis CJD; Morgan SC; Grimes S; Malone J; Kishan AU; Mukherjee D; Spratt DE; Saad F; Malone S
Prostate Cancer Prostatic Dis; 2023 Mar; 26(1):119-125. PubMed ID: 35790787
[TBL] [Abstract][Full Text] [Related]
2. Association of dynamic change in patient-reported pain with survival in metastatic castrate sensitive prostate cancer-exploratory analysis of LATITUDE study.
Roy S; Morgan SC; Wallis CJD; Sun Y; Spratt DE; Malone J; Grimes S; Mukherjee D; Kishan AU; Saad F; Malone S
Prostate Cancer Prostatic Dis; 2023 Mar; 26(1):96-104. PubMed ID: 36097167
[TBL] [Abstract][Full Text] [Related]
3. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial.
Fizazi K; Tran N; Fein L; Matsubara N; Rodriguez-Antolin A; Alekseev BY; Özgüroğlu M; Ye D; Feyerabend S; Protheroe A; Sulur G; Luna Y; Li S; Mundle S; Chi KN
Lancet Oncol; 2019 May; 20(5):686-700. PubMed ID: 30987939
[TBL] [Abstract][Full Text] [Related]
4. Correlation of Prostate-specific Antigen Kinetics with Overall Survival and Radiological Progression-free Survival in Metastatic Castration-sensitive Prostate Cancer Treated with Abiraterone Acetate plus Prednisone or Placebos Added to Androgen Deprivation Therapy: Post Hoc Analysis of Phase 3 LATITUDE Study.
Matsubara N; Chi KN; Özgüroğlu M; Rodriguez-Antolin A; Feyerabend S; Fein L; Alekseev BY; Sulur G; Protheroe A; Li S; Mundle S; De Porre P; Tran N; Fizazi K
Eur Urol; 2020 Apr; 77(4):494-500. PubMed ID: 31843335
[TBL] [Abstract][Full Text] [Related]
5. Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy.
Halabi S; Lin CY; Small EJ; Armstrong AJ; Kaplan EB; Petrylak D; Sternberg CN; Shen L; Oudard S; de Bono J; Sartor O
J Natl Cancer Inst; 2013 Nov; 105(22):1729-37. PubMed ID: 24136890
[TBL] [Abstract][Full Text] [Related]
6. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial.
Chi KN; Protheroe A; Rodríguez-Antolín A; Facchini G; Suttman H; Matsubara N; Ye Z; Keam B; Damião R; Li T; McQuarrie K; Jia B; De Porre P; Martin J; Todd MB; Fizazi K
Lancet Oncol; 2018 Feb; 19(2):194-206. PubMed ID: 29326030
[TBL] [Abstract][Full Text] [Related]
7. Impact of abiraterone acetate plus prednisone in patients with castration-sensitive prostate cancer and visceral metastases over four years of follow-up: A post-hoc exploratory analysis of the LATITUDE study.
Baciarello G; Özgüroğlu M; Mundle S; Leitz G; Richarz U; Hu P; Feyerabend S; Matsubara N; Chi KN; Fizazi K
Eur J Cancer; 2022 Feb; 162():56-64. PubMed ID: 34953443
[TBL] [Abstract][Full Text] [Related]
8. Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer.
Halabi S; Lin CY; Kelly WK; Fizazi KS; Moul JW; Kaplan EB; Morris MJ; Small EJ
J Clin Oncol; 2014 Mar; 32(7):671-7. PubMed ID: 24449231
[TBL] [Abstract][Full Text] [Related]
9. The Phase 3 COU-AA-302 Study of Abiraterone Acetate Plus Prednisone in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Stratified Analysis Based on Pain, Prostate-specific Antigen, and Gleason Score.
Miller K; Carles J; Gschwend JE; Van Poppel H; Diels J; Brookman-May SD
Eur Urol; 2018 Jul; 74(1):17-23. PubMed ID: 28939004
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Score and Benefit from Abiraterone in First-line Metastatic, Castration-resistant Prostate Cancer.
Lorente D; Llacer C; Lozano R; de Velasco G; Romero-Laorden N; Rodrigo M; Sánchez-Iglesias Á; di Capua C; Castro E; Ferrer C; Sánchez-Hernández A; Olmos D
Eur Urol; 2021 Nov; 80(5):641-649. PubMed ID: 34373138
[TBL] [Abstract][Full Text] [Related]
11. Triplet therapy with androgen deprivation, docetaxel, and androgen receptor signalling inhibitors in metastatic castration-sensitive prostate cancer: A meta-analysis.
Ciccarese C; Iacovelli R; Sternberg CN; Gillessen S; Tortora G; Fizazi K
Eur J Cancer; 2022 Sep; 173():276-284. PubMed ID: 35964470
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic Model.
Gravis G; Boher JM; Fizazi K; Joly F; Priou F; Marino P; Latorzeff I; Delva R; Krakowski I; Laguerre B; Walz J; Rolland F; Théodore C; Deplanque G; Ferrero JM; Pouessel D; Mourey L; Beuzeboc P; Zanetta S; Habibian M; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Labourey JL; Machiels JP; El Kouri C; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Soulie M; Oudard S
Eur Urol; 2015 Aug; 68(2):196-204. PubMed ID: 25277272
[TBL] [Abstract][Full Text] [Related]
13. Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial.
Saad F; Thiery-Vuillemin A; Wiechno P; Alekseev B; Sala N; Jones R; Kocak I; Chiuri VE; Jassem J; Fléchon A; Redfern C; Kang J; Burgents J; Gresty C; Degboe A; Clarke NW
Lancet Oncol; 2022 Oct; 23(10):1297-1307. PubMed ID: 36063830
[TBL] [Abstract][Full Text] [Related]
14. Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study.
Agarwal N; McQuarrie K; Bjartell A; Chowdhury S; Pereira de Santana Gomes AJ; Chung BH; Özgüroğlu M; Juárez Soto Á; Merseburger AS; Uemura H; Ye D; Given R; Cella D; Basch E; Miladinovic B; Dearden L; Deprince K; Naini V; Lopez-Gitlitz A; Chi KN;
Lancet Oncol; 2019 Nov; 20(11):1518-1530. PubMed ID: 31578173
[TBL] [Abstract][Full Text] [Related]
15. Development and validation of a prognostic model for overall survival in chemotherapy-naïve men with metastatic castration-resistant prostate cancer.
Armstrong AJ; Lin P; Higano CS; Sternberg CN; Sonpavde G; Tombal B; Templeton AJ; Fizazi K; Phung D; Wong EK; Krivoshik A; Beer TM
Ann Oncol; 2018 Nov; 29(11):2200-2207. PubMed ID: 30202945
[TBL] [Abstract][Full Text] [Related]
16. De novo metastatic castration sensitive prostate cancer: State of art and future perspectives.
Mosillo C; Iacovelli R; Ciccarese C; Fantinel E; Bimbatti D; Brunelli M; Bisogno I; Kinspergher S; Buttigliero C; Tucci M; Caffo O; Tortora G
Cancer Treat Rev; 2018 Nov; 70():67-74. PubMed ID: 30121492
[TBL] [Abstract][Full Text] [Related]
17. Early PSA response is an independent prognostic factor in patients with metastatic castration-resistant prostate cancer treated with next-generation androgen pathway inhibitors.
Fuerea A; Baciarello G; Patrikidou A; Albigès L; Massard C; Di Palma M; Escudier B; Fizazi K; Loriot Y
Eur J Cancer; 2016 Jul; 61():44-51. PubMed ID: 27151554
[TBL] [Abstract][Full Text] [Related]
18. Treating De Novo Metastatic Castration-Sensitive Prostate Cancer With Visceral Metastases: An Evolving Issue.
Roviello G; Petrioli R; Villari D; D'Angelo A
Clin Genitourin Cancer; 2021 Feb; 19(1):83-86. PubMed ID: 32665085
[TBL] [Abstract][Full Text] [Related]
19. Comparison of clinical outcomes between androgen deprivation therapy with up-front abiraterone and bicalutamide for Japanese patients with LATITUDE high-risk prostate cancer in a real-world retrospective analysis.
Naiki T; Takahara K; Ito T; Nakane K; Sugiyama Y; Koie T; Shiroki R; Miyake H; Yasui T
Int J Clin Oncol; 2022 Mar; 27(3):592-601. PubMed ID: 34779958
[TBL] [Abstract][Full Text] [Related]
20. Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer.
Chowdhury S; Bjartell A; Agarwal N; Chung BH; Given RW; Pereira de Santana Gomes AJ; Merseburger AS; Özgüroğlu M; Juárez Soto Á; Uemura H; Ye D; Brookman-May SD; Londhe A; Bhaumik A; Mundle SD; Larsen JS; McCarthy SA; Chi KN
Ann Oncol; 2023 May; 34(5):477-485. PubMed ID: 36858151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
